A specialty healthcare company developing and delivering innovative therapies and services to treat rare diseases
- Sobi has delivered strong operational performance and shareholder return over the last years.
- The company’s strong performance has been driven by the successful launch of two haemophilia products in Europe. Sobi is providing
new innovative treatments for haemophilia patients and was first to market outside the U.S. with a long-acting haemophilia A treatment,
- Going forward, continuing to build a strong and successful haemophilia franchise as well as broadening the product portfolio is key for the company.
Visit the company website